A

Alvotech SA
NASDAQ:ALVO

Watchlist Manager
Alvotech SA
NASDAQ:ALVO
Watchlist
Price: 12.47 USD 4.7% Market Closed
Market Cap: 3.8B USD
Have any thoughts about
Alvotech SA?
Write Note

Alvotech SA
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Alvotech SA
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
A
Alvotech SA
NASDAQ:ALVO
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Alvotech SA
Glance View

Market Cap
3.8B USD
Industry
Biotechnology

In the fiercely competitive world of pharmaceuticals, Alvotech SA has carved out a distinct niche as a specialist in developing biosimilars—essentially highly similar alternatives to already approved biological medicines. Based in Iceland, the company was founded by Robert Wessman, renowned for his successful ventures in the pharmaceutical industry. Alvotech strives to not only make crucial medications more accessible but to also alleviate the strain of high drug costs on healthcare systems worldwide. With its ardent focus on quality and efficacy, Alvotech's innovative research and development strategies underline its commitment to replicating complex biologics, ensuring they are more affordable without compromising on safety and effectiveness. Alvotech’s business model is intricately woven into the fabric of collaboration and partnership. Rather than attempting to market its products independently, Alvotech aligns with a network of global partners for commercialization and distribution, allowing the company to reach diverse markets efficiently. This approach not only widens their reach but also minimizes the cost and time associated with entering new geographical territories. Alvotech generates revenue by selling these biosimilars, capitalizing on the expiration of patents on original biologic drugs. In doing so, it provides healthcare providers and patients with cost-effective options, positioning itself as a valuable player in the increasingly essential biosimilar market.

ALVO Intrinsic Value
17.19 USD
Undervaluation 27%
Intrinsic Value
Price
A

See Also

What is Alvotech SA's Short-Term Debt?
Short-Term Debt
0 USD

Based on the financial report for Dec 31, 2023, Alvotech SA's Short-Term Debt amounts to 0 USD.

Back to Top